Pasithea shares surge 38.68% intraday after $60M public offering and director insider purchases boost investor confidence.

Pasithea Therapeutics (NASDAQ: KTTA) surged 38.68% intraday following a $60 million public offering priced at $0.75 per share, announced on November 28, 2025. The offering, led by healthcare-focused investors, extended the company’s cash runway through 2028 and was declared effective the same day. Concurrently, directors Simon Dumesnil and Lawrence Steinman purchased 33,333 and 133,333 shares, respectively, at $0.75, signaling insider confidence. These events coincided with positive clinical updates, including a $1 million ALS Association grant for PAS-004 trials and favorable safety data from ongoing studies. The combination of capital-raising success, insider buying, and therapeutic progress drove the sharp intraday rally.